In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins

J Infect Dis. 2004 Apr 15;189(8):1440-3. doi: 10.1086/382658. Epub 2004 Apr 1.

Abstract

Cyanovirin-N (CV-N) has been shown to inhibit Ebola Zaire virus (EboZV) infection, both in vitro and in vivo, through its ability to bind to oligomannoses-8/9 on the EboZV surface glycoprotein (GP). Here, we report the in vitro potency of CV-N to inhibit EboZV GP- and Marburg virus GP-pseudotyped viruses (EC50 approximately 40-60 nmol/L and approximately 6-25 nmol/L, respectively) from mediating gene transduction into HeLa cells. In addition, we provide evidence that CV-N can effectively inhibit DC-SIGN-mediated EboZV infection. Our data emphasize both the utility of GP-pseudotyped vectors in the assessment of compounds that affect cell entry by filovirus and the use of CV-N as a reagent for the probing of carbohydrate-dependent interactions at viral entry.

MeSH terms

  • Antiviral Agents / pharmacology*
  • Bacterial Proteins*
  • Carrier Proteins / pharmacology*
  • Ebolavirus / drug effects*
  • Ebolavirus / metabolism
  • Glycoproteins / antagonists & inhibitors
  • Glycoproteins / metabolism
  • HeLa Cells
  • Hemorrhagic Fever, Ebola / prevention & control*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Jurkat Cells
  • Lentivirus / metabolism
  • Marburg Virus Disease / drug therapy*
  • Marburg Virus Disease / virology
  • Marburgvirus / drug effects*
  • Marburgvirus / metabolism
  • Transduction, Genetic
  • Viral Proteins*
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Bacterial Proteins
  • Carrier Proteins
  • Glycoproteins
  • Viral Proteins
  • secreted glycoprotein, Ebola virus
  • cyanovirin N